EMD 103
Alternative Names: EMD-103Latest Information Update: 04 Jan 2021
At a glance
- Originator Emendo biotherapeutics
- Class Gene therapies
- Mechanism of Action Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Bone marrow transplant rejection
Most Recent Events
- 04 Jan 2021 EMD 103 is available for licensing as of 16 Dec 2020. https://emendobio.com/our-technology/
- 16 Dec 2020 Preclinical trials in Bone marrow transplant rejection in USA (Parenteral) before December 2020 (Emendo biotherapeutics pipeline, December 2020)
- 15 Dec 2020 Emendo biotherapeutics has been acquired by AnGes